GlassScriptPhysician profile
Leann Holder
NPI 1376026047
$3,686.32
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $360 · 2022: $783 · 2023: $2,524 · 2024: $19.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,543.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,543.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $592.58 | 2022-2023 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $424.67 | 2022-2023 | Sotyktu |
| Janssen Biotech, INC. | $373.00 | 2022-2023 | Simponi, Simponi Aria, Stelara |
| Abbvie INC. | $332.30 | 2022-2024 | |
| Dermavant Sciences, INC. | $255.05 | 2022-2023 | Vtama |
| Novartis Pharmaceuticals Corporation | $216.79 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $206.57 | 2023 | Dupixent, Libtayo |
| Lilly USA, LLC | $203.98 | 2022-2023 | Olumiant, Taltz |
| Sun Pharmaceutical Industries INC. | $144.77 | 2021-2023 | Winlevi, Blu-U |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $126.59 | 2021 | |
| Incyte Corporation | $107.40 | 2021-2022 | |
| Leo Pharma INC. | $98.90 | 2023 | Adbry |
| Genzyme Corporation | $97.33 | 2022-2023 | |
| Almirall LLC | $78.50 | 2021-2022 | |
| Fresenius Kabi USA, LLC | $77.23 | 2023 | Idacio |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acera Surgical, INC. | $66.63 | 2022 | |
| Mayne Pharma Commercial LLC | $42.44 | 2022 | |
| Galderma Laboratories, L.P. | $38.33 | 2021 | |
| Arcutis Biotherapeutics, INC. | $37.90 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.75 | 2023 | Cyltezo |
| Vyne Pharmaceuticals INC. | $27.23 | 2021 | |
| Genentech USA, INC. | $25.69 | 2021-2022 | |
| Biofrontera INC. | $22.80 | 2022 | |
| Verrica Pharmaceuticals INC. | $21.02 | 2023 | Ycanth |
| Ucb, INC. | $16.80 | 2023 | Bimzelx |
| Journey Medical Corporation | $14.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leann Holder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.